Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis

BACKGROUND: Concomitant use of oral azithromycin and inhaled tobramycin occurs in approximately half of US cystic fibrosis (CF) patients. Recent data suggest that this combination may be antagonistic. METHODS: Test the hypothesis that azithromycin reduces the clinical benefits of tobramycin by analy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cyst Fibros
Autors principals: Nichols, Dave P., Happoldt, Carrie L., Bratcher, Preston E., Caceres, Silvia M., Chmiel, James F., Malcolm, Kenneth C., Saavedra, Milene T., Saiman, Lisa, Taylor-Cousar, Jennifer L., Nick, Jerry A.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5492972/
https://ncbi.nlm.nih.gov/pubmed/28025037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2016.12.003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars